Randomised, double-blind, controlled trials assessing nutritional management, surgical procedures, or global strategies to prevent postoperative recurrence.
| Publication: first author and date . | Treatments evaluated . | Number of patients in each group . | Primary endpoint . | Secondary endpoints . | Primary endpoint result . |
|---|---|---|---|---|---|
| Li 2020 | Mesenteric excision vs limited resection | 116 prevision patients | Surgical recurrence [SR]: subsequent postoperative surgery | ER: Rutgeerts score [RS] >i2 Clinical recurrence [CR]: endoscopic or imaging lesions and symptoms | NA |
| Luglio 2020 | Kono S anastomosis vs conventional surgery [stapled side-to-side anastomosis] | 36 vs 43 | Endoscopic recurrence [ER]: RS >i1 at M6 | ER: M18 CR: M12 and M24 SR: M24 | 22.2% vs 62.8% p < 0.0 |
| Ponsioen 2017 | Ileocaecal resection vs infliximab for terminal ileitis | 73 vs 70 | Disease specific quality of life [IBDQ] | General QoL SF36, adverse events | 178.1 vs 172 p = 0.25 |
| De Cruz 2015 | Colonoscopy at M6 [active care] vs no colonoscopy [standard care] | 122 vs 52 | ER: RS >i1 at M18 [presence and severity] | CR: CDAI >150 or 200 BR: CRP SR Mucosal recurrence | 49% vs 67% p = 0.03 |
| Zhu 2015 | Preoperative nutrition for improvement of malnutrition vs reduction of inflammation | 44 vs 47 | Postoperative complications 4 weeks after surgery | CR: CDAI >150 ER: RS >i1 | 11.4% vs 14.9% p = 0.79 |
| Yamamoto 2007 | Enteral nutrition vs no enteral nutrition | 20 vs 20 | ER: RS >i1 at M12 CR: CDAI >150 ER | ER: RS >i1 at M12 BR: CRP, albumin | 30% vs 70% [ER] p = 0.03 |
| Cameron 1992 | End-to-end vs side to-end anastomosis | 47 vs 39 | CR: symptoms 'Documented recurrences': endoscopy/radiology/surgery: no further precisions | 23% vs 31% [documented] p = NS |
| Publication: first author and date . | Treatments evaluated . | Number of patients in each group . | Primary endpoint . | Secondary endpoints . | Primary endpoint result . |
|---|---|---|---|---|---|
| Li 2020 | Mesenteric excision vs limited resection | 116 prevision patients | Surgical recurrence [SR]: subsequent postoperative surgery | ER: Rutgeerts score [RS] >i2 Clinical recurrence [CR]: endoscopic or imaging lesions and symptoms | NA |
| Luglio 2020 | Kono S anastomosis vs conventional surgery [stapled side-to-side anastomosis] | 36 vs 43 | Endoscopic recurrence [ER]: RS >i1 at M6 | ER: M18 CR: M12 and M24 SR: M24 | 22.2% vs 62.8% p < 0.0 |
| Ponsioen 2017 | Ileocaecal resection vs infliximab for terminal ileitis | 73 vs 70 | Disease specific quality of life [IBDQ] | General QoL SF36, adverse events | 178.1 vs 172 p = 0.25 |
| De Cruz 2015 | Colonoscopy at M6 [active care] vs no colonoscopy [standard care] | 122 vs 52 | ER: RS >i1 at M18 [presence and severity] | CR: CDAI >150 or 200 BR: CRP SR Mucosal recurrence | 49% vs 67% p = 0.03 |
| Zhu 2015 | Preoperative nutrition for improvement of malnutrition vs reduction of inflammation | 44 vs 47 | Postoperative complications 4 weeks after surgery | CR: CDAI >150 ER: RS >i1 | 11.4% vs 14.9% p = 0.79 |
| Yamamoto 2007 | Enteral nutrition vs no enteral nutrition | 20 vs 20 | ER: RS >i1 at M12 CR: CDAI >150 ER | ER: RS >i1 at M12 BR: CRP, albumin | 30% vs 70% [ER] p = 0.03 |
| Cameron 1992 | End-to-end vs side to-end anastomosis | 47 vs 39 | CR: symptoms 'Documented recurrences': endoscopy/radiology/surgery: no further precisions | 23% vs 31% [documented] p = NS |
ER: endoscopic recurrence; RS: Rutgeerts score; CR: clinical recurrence; CDAI: Crohn’s disease activity index; IR: imaging recurrence; CRP: C reactive protein; BR: biological recurrence.
Randomised, double-blind, controlled trials assessing nutritional management, surgical procedures, or global strategies to prevent postoperative recurrence.
| Publication: first author and date . | Treatments evaluated . | Number of patients in each group . | Primary endpoint . | Secondary endpoints . | Primary endpoint result . |
|---|---|---|---|---|---|
| Li 2020 | Mesenteric excision vs limited resection | 116 prevision patients | Surgical recurrence [SR]: subsequent postoperative surgery | ER: Rutgeerts score [RS] >i2 Clinical recurrence [CR]: endoscopic or imaging lesions and symptoms | NA |
| Luglio 2020 | Kono S anastomosis vs conventional surgery [stapled side-to-side anastomosis] | 36 vs 43 | Endoscopic recurrence [ER]: RS >i1 at M6 | ER: M18 CR: M12 and M24 SR: M24 | 22.2% vs 62.8% p < 0.0 |
| Ponsioen 2017 | Ileocaecal resection vs infliximab for terminal ileitis | 73 vs 70 | Disease specific quality of life [IBDQ] | General QoL SF36, adverse events | 178.1 vs 172 p = 0.25 |
| De Cruz 2015 | Colonoscopy at M6 [active care] vs no colonoscopy [standard care] | 122 vs 52 | ER: RS >i1 at M18 [presence and severity] | CR: CDAI >150 or 200 BR: CRP SR Mucosal recurrence | 49% vs 67% p = 0.03 |
| Zhu 2015 | Preoperative nutrition for improvement of malnutrition vs reduction of inflammation | 44 vs 47 | Postoperative complications 4 weeks after surgery | CR: CDAI >150 ER: RS >i1 | 11.4% vs 14.9% p = 0.79 |
| Yamamoto 2007 | Enteral nutrition vs no enteral nutrition | 20 vs 20 | ER: RS >i1 at M12 CR: CDAI >150 ER | ER: RS >i1 at M12 BR: CRP, albumin | 30% vs 70% [ER] p = 0.03 |
| Cameron 1992 | End-to-end vs side to-end anastomosis | 47 vs 39 | CR: symptoms 'Documented recurrences': endoscopy/radiology/surgery: no further precisions | 23% vs 31% [documented] p = NS |
| Publication: first author and date . | Treatments evaluated . | Number of patients in each group . | Primary endpoint . | Secondary endpoints . | Primary endpoint result . |
|---|---|---|---|---|---|
| Li 2020 | Mesenteric excision vs limited resection | 116 prevision patients | Surgical recurrence [SR]: subsequent postoperative surgery | ER: Rutgeerts score [RS] >i2 Clinical recurrence [CR]: endoscopic or imaging lesions and symptoms | NA |
| Luglio 2020 | Kono S anastomosis vs conventional surgery [stapled side-to-side anastomosis] | 36 vs 43 | Endoscopic recurrence [ER]: RS >i1 at M6 | ER: M18 CR: M12 and M24 SR: M24 | 22.2% vs 62.8% p < 0.0 |
| Ponsioen 2017 | Ileocaecal resection vs infliximab for terminal ileitis | 73 vs 70 | Disease specific quality of life [IBDQ] | General QoL SF36, adverse events | 178.1 vs 172 p = 0.25 |
| De Cruz 2015 | Colonoscopy at M6 [active care] vs no colonoscopy [standard care] | 122 vs 52 | ER: RS >i1 at M18 [presence and severity] | CR: CDAI >150 or 200 BR: CRP SR Mucosal recurrence | 49% vs 67% p = 0.03 |
| Zhu 2015 | Preoperative nutrition for improvement of malnutrition vs reduction of inflammation | 44 vs 47 | Postoperative complications 4 weeks after surgery | CR: CDAI >150 ER: RS >i1 | 11.4% vs 14.9% p = 0.79 |
| Yamamoto 2007 | Enteral nutrition vs no enteral nutrition | 20 vs 20 | ER: RS >i1 at M12 CR: CDAI >150 ER | ER: RS >i1 at M12 BR: CRP, albumin | 30% vs 70% [ER] p = 0.03 |
| Cameron 1992 | End-to-end vs side to-end anastomosis | 47 vs 39 | CR: symptoms 'Documented recurrences': endoscopy/radiology/surgery: no further precisions | 23% vs 31% [documented] p = NS |
ER: endoscopic recurrence; RS: Rutgeerts score; CR: clinical recurrence; CDAI: Crohn’s disease activity index; IR: imaging recurrence; CRP: C reactive protein; BR: biological recurrence.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
